| Literature DB >> 22654879 |
Giorgia Gri1, Barbara Frossi, Federica D'Inca, Luca Danelli, Elena Betto, Francesca Mion, Riccardo Sibilano, Carlo Pucillo.
Abstract
Mast cells (MCs) are currently recognized as effector cells in many settings of the immune response, including host defense, immune regulation, allergy, chronic inflammation, and autoimmune diseases. MC pleiotropic functions reflect their ability to secrete a wide spectrum of preformed or newly synthesized biologically active products with pro-inflammatory, anti-inflammatory and/or immunosuppressive properties, in response to multiple signals. Moreover, the modulation of MC effector phenotypes relies on the interaction of a wide variety of membrane molecules involved in cell-cell or cell-extracellular-matrix interaction. The delivery of co-stimulatory signals allows MC to specifically communicate with immune cells belonging to both innate and acquired immunity, as well as with non-immune tissue-specific cell types. This article reviews and discusses the evidence that MC membrane-expressed molecules play a central role in regulating MC priming and activation and in the modulation of innate and adaptive immune response not only against host injury, but also in peripheral tolerance and tumor-surveillance or -escape. The complex expression of MC surface molecules may be regarded as a measure of connectivity, with altered patterns of cell-cell interaction representing functionally distinct MC states. We will focalize our attention on roles and functions of recently discovered molecules involved in the cross-talk of MCs with other immune partners.Entities:
Keywords: adaptive immunity; cell–cell interaction; innate immunity; mast cell
Year: 2012 PMID: 22654879 PMCID: PMC3360165 DOI: 10.3389/fimmu.2012.00120
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
MC membrane-bound receptors.
| Receptor family | Members | Reference |
|---|---|---|
| FcεR | FcεRI | Kinet ( |
| FcγR | FcγRIa, FcγRII, FcγRIIIb | Malbec and Daëron ( |
| TLR | TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10a | Marshal et al. ( |
| MHC | MHC class I, MHC class II | Svensson et al. ( |
| Complement receptor | CR1, CR2, CR3, CR4, CR5, C3aR, C5aR | Füreder et al. ( |
| Cytokine receptor | CD117, IL-1R, IL-3R, IL-10R, IL-12R, INFγR, TGFβR | Edling and Hallberg ( |
| Chemokine receptor | CCR1, CCR3, CCR4, CCR5,CCR7, CXCR1, CXCR2, CXCR3, CXCR4, CXCR6, CX3CR1 | Juremalm and Nilsson, (2005) |
| Histamine receptor | H1/H2/H3/H4 receptor | Sander et al. ( |
| Others | Endothelin-1, neurotensin, substance P, PGE2, adenosine | Galli et al. ( |
| Adhesion molecules | ICAM-1, VCAM, VLA4, CD226 (DNAM-1), Siglec8, CD47, CD300a, CD72 | Hudson et al. ( |
| TNF/TNFR family members | CD40L, OX40L, 4-1BB, GITR, CD153, Fas, TRAIL-R | Juremalm and Nilsson ( |
| B7 family member | CD28, ICOSL, PD-L1, PD-L2 | |
| TIM family members | TIM1, TIM3 | |
| Notch family members | Notch1, Notch2 | |
Some molecules have been detected only in studies on human.
Major MC-derived mediators.
| Class | Mediators | Physiological effects |
|---|---|---|
| Biogenic amines | Histamine | Vasodilatation |
| 5-hydroxytryptamine | Leukocyte regulation, pain, vasoconstriction | |
| Proteoglycans | Heparin, heparin sulfate | Angiogenesis, coagulation |
| Chondroitin sulfate | Tissue remodeling | |
| Proteases | Tryptase | Inflammation, pain, tissue damage, PAR activation |
| Chymase | Inflammation, pain, tissue damage | |
| MC-CPA/Carboxypeptidase A | Enzyme degradation | |
| CathepsinB, C, D, E, G, L, Sb | Pathogen killing, tissue remodeling | |
| MCP5/6 | Pathogenesis of asthma and other allergic disorders | |
| Lysosomial enzymes | β-hexosaminidase, β-glucuronidase, β-galactosidase, arylsulfataseA | ECM remodeling |
| Others | Nitric oxide synthase | NO production |
| Endothelin | Sepsis | |
| Kinins | Inflammation, pain, vasodilatation | |
| Anti-inflammatory effects | ||
| Lipid-derived | LTB4, LTC4, PGD2, PAF | Inflammation, leukocyte recruitment, endothelial adhesion, |
| Cytokines | IL-1αa, IL-1βa, IL-2b, IL-3, IL-4, IL-5, IL-6, IL8a, IL-9, IL-10, IL-11a, IL-12, IL-13, IL-14a, IL-15a, IL-16, IL-17, IL-18a, IL-22b, IL-25b, IL-33b, MIF, TNFα, IFNα, IFNβb, IFNγb | Inflammation, leukocyte proliferation and activation immunoregulation |
| Chemokines | CCL1, CCL2, CCL3a,b, CCL4a CCL5a, CCL7a,b, CCL8a, CCL11a, CCL13a, CCL16a, CCL17, CCL19a, CCL20a, CCL22a,b, CCL25b CXCL1a, CXCL2, CXCL3a, CXCL4, CXCL5, CXCL8a, CXCL10a, CX3CL | Leukocyte chemotaxis |
| Growth factors | TGFβ, SCFa, G-CSF, M-CSF, GM-CSF, VEGF, NGFβ, LIFa, bFGF | Growth of various cell types |
| Antimicrobic species | Antimicrobial peptides, NO, superoxide, ROS | Pathogen killing |
Some mediators have been detected only in studies on human .
General references: Galli et al. (.
MC physical interactions with other immune cells.
| Cell types | MC molecule | Partner molecule | Effect on MC | Effect on partner cell | Reference |
|---|---|---|---|---|---|
| MC-DC | ICAM-1 | LFA-1 | ↑ Ca++ influx | ↑ Maturation and chemotaxis | Otsuka et al. ( |
| MC-MDSC | n.i. | n.i. | ↑ Recruitment and survival | ↑ Migration and suppression activity | Yang et al. ( |
| MC-NK | CXCL8 | CXCR1 | n.i. | ↑ Recruitment | Burke et al. ( |
| OX40L | OX40 | n.i. | IFNγ production | Vosskuhl et al. ( | |
| MC-Eos | CD226 | CD112 | ↑ Degranulation | n.i. | Bachelet et al. ( |
| CD48 | 2B.4 | n.i. | ↑Survival | Elishmereni et al. ( | |
| n.i. | n.i. | Transfer of tryptase | ↑EPO and cytokine release, transfer of EPO | Minai-Fleminger et al. ( | |
| MC-CD4+T | ICAM-1 | LAF-1 | ↑ Degranulation and cytokine release | ↑ Activation and proliferation | Inamura et al. ( |
| ICAM-1 | LFA-1 | Adhesion to endothelial cell | n.i. | Brill et al. ( | |
| LTβR | LTβR ligand | ↑ Cytokine release | n.i. | Stopfer et al. ( | |
| OX40L | OX40 | n.i. | ↑ Activation and proliferation | Frandji et al. ( | |
| MHC-II | TCR | n.i. | Cell activation | Kashiwakura et al. ( | |
| ICOSL | ICOS | n.i. | Switch to IL-10 regulatory T | Gaudenzio et al. ( | |
| MC-CD+8 | MHC-I | TCR | n.i. | Cell activation | Malaviya et al. ( |
| MHC-I | TCR | ↑ Expression of co-stimulatory molecules and degranulation | Cell activation | Stelekati et al. ( | |
| MC + Treg | OX40L | OX40 | ↓ Degranulation | ↓ Suppressive activity, conversion to Th17 | Gri et al. ( |
| TGFβR | TGFβ membrane-bound | ↓ Degranulation, ↑ IL-6 production | ↓ Suppressive activity | Ganeshan and Bryce ( | |
| MC + B | CD40L | CD40 | n.i. | ↑ Proliferation and Ig switch | Gauchat et al. ( |
n.i., not investigated.